Celcuity Q3 net loss $10.9M ($0.75/sh); Phase 3 VIKTORIA-1 site activation underway

Celcuity Inc.

2023-Q3 EPS reported -$1.95

Net loss $10.9M ($0.75/sh) vs $6.0M ($0.41/sh) in Q3 2021; adjusted net loss $9.5M ($0.63/sh).
R&D expenses $9.6M, up $4.7M YoY, mainly from VIKTORIA-1 trial initiation and existing trials.
Completed selection of 200 clinical sites for Phase 3 VIKTORIA-1; first site activated; first dosing expected by end of 2022.
FDA granted Breakthrough Therapy designation for gedatolisib in July; $100M private placement to close after first patient dose.
Appointed Polly Murphy to Board; Phase 1b update accepted for December 2022 San Antonio Breast Cancer Symposium.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celcuity Inc. reported the third quarter ended September 30, 2022 results: net income $10.9 million, or $0.75 loss per share, EPS $0.75 loss per share.

Period: the third quarter ended September 30, 2022
Net income: $10.9 million, or $0.75 loss per share
EPS: $0.75 loss per share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $10.9 million, or $0.75 loss per share, compared to a net loss of $6.0 million, or $0.41 loss per share, for the third quarter of 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.